🔍

TORNTPHARM - Torrent Pharma.

📊 NSE: TORNTPHARM 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 14:26

📢 Recent Corporate Announcements

Torrent Pharma Shareholders Approve Merger with J.B. Chemicals with 100% Votes in Favor

🟢 POSITIVE ⭐ 9/10

M&A 📅 28 Apr 2026, 10:56 PM

Torrent Pharmaceuticals' shareholders have overwhelmingly approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited. In an NCLT-convened meeting held on April 28, 2026, 100% of the valid votes cast by value were in favor of the merger. The consolidated voting results showed participation from 1,202 shareholders, representing over 31.73 crore votes. This approval marks a critical step in the regulatory process for the merger of these two pharmaceutical companies.

100% of valid votes by value were cast in favor of the amalgamation with J.B. Chemicals & Pharmaceuticals.
A total of 31,73,30,454 votes were polled, representing a value of INR 1,58,66,52,270.
Promoter group cast 23,11,85,400 votes, all of which were in favor of the resolution.
Public shareholders cast 8,38,11,400 valid votes, with only 341 votes cast against the scheme.
The meeting was conducted via video conferencing as per the NCLT Ahmedabad Bench order dated March 23, 2026.

💡 The strong shareholder mandate clears a major hurdle for the merger; investors should now monitor the final NCLT sanction and the subsequent integration of J.B. Chemicals' portfolio.

Torrent Pharma Shareholders Approve Merger with J.B. Chemicals & Pharmaceuticals

🟢 POSITIVE ⭐ 9/10

M&A 📅 28 Apr 2026, 09:06 PM

Shareholders of Torrent Pharmaceuticals have officially approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals Limited in an NCLT-convened meeting held on April 28, 2026. The resolution was passed with the requisite majority, satisfying the requirement of a majority in number and three-fourths in value of the shareholders who cast their votes. This approval is a critical milestone in the merger process, which aims to consolidate the operations of both pharmaceutical entities. The company will now proceed with the remaining regulatory steps to finalize the transaction.

Shareholders approved the merger of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited.
The resolution passed with a majority in number and 75% in value of the equity shareholders who voted.
The NCLT-convened meeting was conducted via video conferencing on April 28, 2026, concluding in 21 minutes.
Compliance with Section 230(6) of the Companies Act, 2013, has been achieved for this shareholder vote.

💡 Investors should view this as a positive step toward scale and synergy; monitor the final NCLT approval and the subsequent integration process for long-term value creation.

Torrent Pharma's Bileshwarpura Oncology Unit Gets Zero USFDA Observations

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 10 Apr 2026, 07:07 PM

Torrent Pharmaceuticals has successfully cleared a USFDA inspection at its Bileshwarpura oncology facility. The audit, which took place from April 6 to April 10, 2026, concluded with zero observations. This clean report indicates that the facility meets the stringent quality standards required for the US market. Such regulatory clearances are vital for maintaining existing product sales and securing approvals for new drug applications in the oncology segment.

USFDA inspection of the Bileshwarpura (Oncology) facility concluded on April 10, 2026.
The audit resulted in zero observations, meaning no Form 483 was issued by the regulator.
The inspection spanned five days, starting from April 6, 2026.
Successful compliance strengthens the company's position and growth prospects in the US oncology market.

💡 The zero-observation status is a strong positive signal for the company's manufacturing quality and reduces regulatory risk. Investors should view this as a positive development for the company's US-bound oncology pipeline.

Torrent Pharma Sells Stake in UNM Foundation to Promoter for ₹5 Lakh

🟡 NEUTRAL ⭐ 2/10

OTHER 📅 30 Mar 2026, 08:08 PM

Torrent Pharmaceuticals has divested its stake in UNM Foundation, a Section 8 associate company, by selling 50,000 equity shares. The shares were sold to the company's promoter and holding entity, Torrent Investments Limited, for a total consideration of ₹5,00,000. As UNM Foundation is a non-profit entity, it had no contribution to Torrent Pharma's revenue or turnover. The transaction was completed on March 30, 2026, and is classified as a related party transaction conducted at arm's length.

Sale of 50,000 equity shares of UNM Foundation at ₹10 face value each
Total cash consideration received amounts to ₹5,00,000
Buyer is Torrent Investments Limited, the holding company and promoter group entity
UNM Foundation is a Section 8 company with zero revenue contribution to the listed entity
Transaction completed on March 30, 2026, at 19:40 pm

💡 This is a minor administrative transaction involving a non-profit associate and has no impact on the company's financial health or core operations. No action is required from investors.

Torrent Pharma Trading Window to Close from April 1, 2026 for FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Mar 2026, 12:25 PM

Torrent Pharmaceuticals Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of the company's audited financial results for the fiscal year ending March 31, 2026. The trading window will remain closed until 48 hours after the financial results are submitted to the stock exchanges. This is a routine administrative filing and does not reflect any change in the company's business operations or financial health.

Trading window for designated persons closed effective April 1, 2026.
Closure pertains to the finalization of Audited Financial Results for the FY ended March 31, 2026.
The window will reopen 48 hours after the financial results are officially disclosed to BSE and NSE.
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's internal Code of Conduct.

💡 No action is required as this is a standard regulatory procedure. Investors should monitor the company's upcoming announcements for the specific date of the FY26 earnings release.

Torrent Pharma to Hold Shareholder Meeting on April 28 for J.B. Chemicals Merger

🟢 POSITIVE ⭐ 10/10

M&A 📅 28 Mar 2026, 10:42 AM

Torrent Pharmaceuticals has scheduled a court-convened meeting on April 28, 2026, to seek shareholder approval for the merger of J.B. Chemicals & Pharmaceuticals Limited into the company. This follows a National Company Law Tribunal (NCLT) order dated March 23, 2026, marking a significant step in the consolidation process. The merger is supported by fairness opinions from Axis Capital and ICICI Securities and a joint valuation report from E&Y and BDO. This strategic move aims to strengthen Torrent's market position through the integration of J.B. Chemicals' portfolio.

Court-convened meeting for equity shareholders scheduled for April 28, 2026, at 10:00 a.m. IST.
Remote e-voting period set from April 24, 2026, to April 27, 2026, with a cut-off date of April 21, 2026.
The scheme involves the complete amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals.
Fairness opinions and valuation reports were finalized in June 2025, with SEBI observation letters received in February 2026.
The merger is being conducted under Sections 230 to 232 of the Companies Act, 2013.

💡 Investors should review the scheme of amalgamation and participate in the voting process, as this merger is a major growth driver for the company. Monitor the subsequent NCLT final approval and integration timelines for potential synergy benefits.

Torrent Pharma Sets April 28 Meeting for Shareholder Approval of J.B. Chemicals Merger

🟢 POSITIVE ⭐ 10/10

M&A 📅 27 Mar 2026, 08:24 PM

Torrent Pharmaceuticals has scheduled a court-convened meeting on April 28, 2026, to seek shareholder approval for the merger of J.B. Chemicals & Pharmaceuticals Limited into the company. The merger process follows an NCLT order dated March 23, 2026, and previous observation letters from BSE and NSE received in February 2026. Shareholders as of the cut-off date of April 21, 2026, are eligible to vote on the resolution. This consolidation is a major strategic move aimed at expanding Torrent's market share and therapeutic reach in the pharmaceutical sector.

Court-convened meeting scheduled for April 28, 2026, to approve the Scheme of Amalgamation.
Cut-off date for voting eligibility is April 21, 2026, with remote e-voting from April 24 to April 27.
BSE and NSE issued observation letters for the merger on February 17, 2026.
Joint Share Exchange Ratio Report and Fairness Opinions were finalized on June 29, 2025.
The merger involves J.B. Chemicals & Pharmaceuticals Limited as the Transferor Company.

💡 Investors should review the share exchange ratio and merger documents to understand the long-term synergy benefits. Participation in the e-voting process is recommended to support this significant corporate consolidation.

Torrent Pharma Receives NCLT Corrigendum Order for J.B. Chemicals Amalgamation

🟢 POSITIVE ⭐ 8/10

M&A 📅 25 Mar 2026, 08:05 PM

Torrent Pharmaceuticals has received a corrigendum order from the NCLT Ahmedabad Bench regarding its proposed amalgamation with J.B. Chemicals & Pharmaceuticals Limited. This follows the initial order dated March 24, 2026, and represents a procedural legal step in the merger process. The amalgamation aims to consolidate the operations of J.B. Chemicals into Torrent Pharma to drive synergies. The official order was uploaded to the NCLT website on March 25, 2026, for public record.

NCLT Ahmedabad Bench issued a Corrigendum Order on March 24, 2026, regarding the merger.
The order pertains to the Scheme of Amalgamation between J.B. Chemicals & Pharmaceuticals and Torrent Pharma.
The document was officially uploaded to the NCLT website on March 25, 2026.
This update follows the company's previous regulatory intimation dated March 24, 2026.

💡 Investors should monitor the final approval timelines and integration plans as the merger could significantly impact market share and operational efficiency. No immediate portfolio changes are required based on this procedural update.

Torrent Pharma Receives NCLT First Motion Order for J.B. Chemicals Amalgamation

🟢 POSITIVE ⭐ 8/10

M&A 📅 24 Mar 2026, 07:08 PM

Torrent Pharmaceuticals has achieved a procedural milestone in its proposed merger with J.B. Chemicals & Pharmaceuticals Limited. The Hon’ble National Company Law Tribunal (NCLT), Ahmedabad Bench, uploaded the order for the first motion application on March 23, 2026. This development follows the initial amalgamation announcement made on June 29, 2025. The merger is expected to consolidate the market position of Torrent Pharma once all regulatory approvals are finalized.

NCLT Ahmedabad Bench uploaded the first motion order on March 23, 2026.
The scheme involves the amalgamation of J.B. Chemicals & Pharmaceuticals into Torrent Pharmaceuticals.
The merger process was originally initiated and disclosed to exchanges on June 29, 2025.
This legal step indicates steady progress in the regulatory approval timeline for the M&A activity.

💡 Investors should view this as a positive step toward the completion of a significant acquisition. Monitor for subsequent NCLT hearings and the final order to assess the impact on the company's consolidated financials.

Torrent Pharma Launches Generic Semaglutide (Oral & Injectable) Starting at Rs 3,999/Month

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 21 Mar 2026, 02:00 PM

Torrent Pharmaceuticals has entered the high-growth GLP-1 therapy segment by launching generic Semaglutide under the brands Sembolic and Semalix. It is the first Indian company to offer generic oral formulations, alongside an injectable version priced competitively at Rs 3,999 per month. This move targets the massive Type-2 diabetes and obesity market in India, leveraging Torrent's 5th rank in the Indian Pharma Market. With approximately 76% of its domestic revenue derived from chronic therapies, this launch significantly strengthens its core portfolio.

First Indian company to launch generic oral semaglutide formulations in the domestic market.
Injectable semaglutide launched with a competitive starting price of Rs 3,999 per month.
Targets the metabolic disorder segment, addressing Type-2 diabetes and obesity management.
Strengthens Torrent's chronic therapy portfolio, which accounts for ~76% of its India revenues.
Torrent Pharma maintains a strong market position with annual revenues exceeding Rs 11,500 crores.

💡 Investors should monitor the adoption rate of these generic formulations as they disrupt a high-value therapeutic segment. This launch is a significant growth catalyst for Torrent's domestic chronic business.

Torrent Pharma to Hold Institutional Investor Meetings in Singapore, HK, and London

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 07:26 PM

Torrent Pharmaceuticals has announced a series of international institutional investor meetings scheduled from March 2 to March 12, 2026. The company will engage with investors in Singapore (March 2-4), Hong Kong (March 5-6), and London (March 9-12). These interactions will include both group and one-on-one formats to discuss the company's performance and outlook. This is a routine regulatory disclosure under SEBI LODR regulations to ensure transparency with the global investment community.

Meetings scheduled across three major global financial hubs: Singapore, Hong Kong, and London.
The engagement period spans 11 days from March 2, 2026, to March 12, 2026.
Interaction formats include both group sessions and one-on-one meetings with institutional investors.
Disclosure made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).

💡 No immediate action is required as this is a routine investor relations event. Investors should monitor for any investor presentations or transcripts released post-meetings for insights into growth strategy.

Torrent Pharma Releases Q3 FY25-26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 06:46 PM

Torrent Pharmaceuticals has officially released the transcript of its conference call with analysts and investors regarding the financial results for Q3 and the nine months ended December 31, 2025. The filing follows the initial earnings announcement made on February 2, 2026, providing a detailed record of management's commentary and responses to investor queries. This document is a standard regulatory requirement under SEBI LODR Regulations to ensure transparency. Investors can access the full discussion on the company's website to gain deeper insights into operational performance.

Official transcript for Q3 and 9M FY25-26 earnings call is now publicly available.
Filing complies with Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The transcript covers management's detailed discussion on financial performance for the period ending December 31, 2025.
The document is hosted on the company's official investor relations portal for public access.

💡 Investors should review the transcript for specific management guidance on domestic market growth and margin sustainability. No immediate action is required as this is a routine administrative disclosure.

Torrent Pharma Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 07:45 PM

Torrent Pharmaceuticals has officially released the audio recording of its conference call with analysts and investors regarding the financial results for the quarter and nine months ended December 31, 2025. This filing is a standard regulatory requirement under SEBI LODR Regulations to ensure transparency in management communications. The recording allows stakeholders to hear direct commentary on the company's performance and strategic outlook. The call follows the initial financial results announcement previously disclosed on February 2, 2026.

Audio recording for Q3 and 9M FY26 results is now available on the company website.
The disclosure is made pursuant to Regulation 30(6) of SEBI (LODR) Regulations, 2015.
The conference call follows the financial results declared on February 2, 2026.
Provides access to management's detailed discussion on operational and financial metrics.

💡 Investors should review the audio recording for qualitative insights into the company's domestic market growth and margin guidance. This is a routine compliance update and does not necessitate any immediate investment action.

Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:10 PM

Torrent Pharmaceuticals reported a strong performance for Q3 FY2025-26, with net profit increasing 19% year-on-year to ₹577 crores. Revenue from operations grew to ₹2,599 crores compared to ₹2,377 crores in the same quarter last year. The company's board declared a substantial interim dividend of ₹29 per share (580% of face value), with a payout expected by March 6, 2026. For the nine-month period, the company has shown consistent growth, with total profit reaching ₹1,725 crores against ₹1,414 crores in the previous year.

Net profit for Q3 FY26 rose 19% YoY to ₹577 crores from ₹485 crores.
Revenue from operations increased to ₹2,599 crores, up from ₹2,377 crores in Q3 FY25.
Declared an interim dividend of ₹29 per equity share (580% of face value).
Earnings Per Share (EPS) for the quarter improved to ₹17.04 from ₹14.33 YoY.
Nine-month total income grew to ₹7,937 crores compared to ₹7,266 crores in the prior year period.

💡 Investors should consider the strong bottom-line growth and healthy dividend payout as positive indicators of operational efficiency. The stock remains a robust pick for those seeking a combination of growth and regular income.

Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:06 PM

Torrent Pharmaceuticals reported a strong performance for Q3 FY26, with revenue from operations growing to ₹2,599 crore compared to ₹2,377 crore in the same quarter last year. Net profit saw a significant jump of approximately 19% year-on-year, reaching ₹577 crore. The company also announced a substantial interim dividend of ₹29 per equity share, representing 580% of the face value. For the nine-month period ended December 2025, the company maintained momentum with a net profit of ₹1,725 crore against ₹1,414 crore in the previous year.

Revenue from operations increased by 9.3% YoY to ₹2,599 crore in Q3 FY26
Net profit for the quarter grew by 19% YoY to ₹577 crore from ₹485 crore
Board declared an interim dividend of ₹29 per share (580%) with payment expected by March 6, 2026
Basic and Diluted EPS improved to ₹17.04 for the quarter compared to ₹14.33 in the previous year's quarter
9M FY26 net profit stands at ₹1,725 crore, showing a robust 22% growth over 9M FY25

💡 Investors should view the consistent double-digit profit growth and high dividend payout as a sign of strong operational health. The stock remains a solid hold for long-term investors looking for steady earnings growth and dividend income.

View All TORNTPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenues grew 7% to INR 11,516 Cr in FY25. In Q2 FY26, India business grew 12% to INR 1,820 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%. US business grew 26% in Q2 FY26, while Brazil grew 21% (13% in constant currency). Germany grew 5% in Q2 FY26, though it declined 5% in constant currency due to supply disruptions.

Geographic Revenue Split

India is the largest market contributing 55% of total revenue (INR 6,393 Cr in FY25). Branded markets collectively accounted for 73% of overall revenue in Q2 FY26. Other key regions include Brazil, Germany, and the USA.

Profitability Margins

Gross Profit margin improved to 76% in FY25 from 75% in FY24. Net profit margin (adjusted for exceptions) stood at 16.6% in FY25 compared to 15.4% in FY24. Profit After Tax (PAT) grew 15.4% to INR 1,911 Cr in FY25 from INR 1,656 Cr in FY24.

EBITDA Margin

Operating EBITDA margin was 32% in FY25 (INR 3,721 Cr), up from 31% (INR 3,368 Cr) in FY24. For Q2 FY26, the EBITDA margin further improved to 32.8% (INR 1,083 Cr), representing a 15% YoY growth in EBITDA value.

Capital Expenditure

Total R&D expenditure, including capital expenses, was INR 431.53 Cr in FY25. The company also maintains an enabling resolution to raise funds through a Qualified Institutional Placement (QIP) for large acquisitions like JB Chemicals.

Credit Rating & Borrowing

The company reduced borrowings by INR 911 Cr in FY25. Net leverage (Net Debt to EBITDA) improved from 0.62x in FY25 to 0.45x in Q2 FY26. ICRA notes that leverage may rise to ~2.2x by March 2027 following the JB Chemicals acquisition, which is being funded entirely through debt.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (API) and other formulation materials are the primary inputs. While specific % of total cost per material is not disclosed, Gross Profit margin of 76% indicates raw material costs are approximately 24% of revenue.

Import Sources

Sourced from both domestic and foreign suppliers to support global manufacturing operations across India, Germany, and Brazil.

Key Suppliers

Not specifically named, but the company utilizes both in-house API manufacturing and third-party vendors. A disruption at a specific third-party supplier in Germany caused a 5% constant currency revenue decline in that market in Q2 FY26.

Capacity Expansion

The company operates key manufacturing facilities at Dahej and Indrad. Future growth is tied to the integration of JB Chemicals' manufacturing operations and supply chains to capture cost synergies.

Raw Material Costs

Raw material costs are managed through alternate sourcing strategies and vertical integration. Gross profit increased by 9% YoY to INR 8,740 Cr in FY25, reflecting efficient procurement despite a 7% revenue increase.

Manufacturing Efficiency

Efficiency is driven by increasing operating leverage and cost control. Operating margins improved to 32.2% in 9M FY25 from 29.5% in FY23 due to better capacity utilization and branded market focus.

Logistics & Distribution

Distribution is managed through a global footprint; logistics optimization and rate contracts with vendors are used to rationalize costs.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth is driven by the acquisition of JB Chemicals (INR 25,689 Cr valuation) to gain scale in cardiology and gastro segments. In India, the company targets outperforming the IPM through its chronic business (currently growing at 13%). US growth is expected to accelerate following USFDA EIR/VAI status at Dahej and Indrad, enabling more than the previous 2 launches per year.

Products & Services

Branded and generic pharmaceutical formulations in therapeutic segments including Cardiovascular (CVS), Gastrointestinal (GI), Central Nervous System (CNS), and vitamins/nutrients.

Brand Portfolio

Torrent Pharma, Heumann Pharma (Germany), and soon-to-be-integrated brands from JB Chemicals and Pharmaceuticals.

New Products/Services

New launches in India and the US are key drivers; US growth of 26% in Q2 FY26 was significantly aided by new product volume and market share gains.

Market Expansion

Expansion is focused on branded generic markets (India, Brazil, SE Asia) and strengthening the German tender business. The JB Chemicals acquisition expands the footprint in India and South Africa.

Market Share & Ranking

Torrent is the 5th largest player in the Indian pharmaceutical market. It has achieved target market shares in new US launches.

Strategic Alliances

Acquisition of a 46.39% stake in JB Chemicals from KKR for INR 11,917 Cr, followed by a mandatory open offer for 26% and an eventual merger.

🌍 External Factors

Industry Trends

The industry is shifting toward branded generics and chronic therapies to ensure stable cash flows. Torrent is positioned as a leader in this shift, with 73% of revenue from branded markets.

Competitive Landscape

Competes with large Indian pharma players and global generic companies. Competition in the US generics market remains intense with persistent price erosion.

Competitive Moat

Moat is built on a strong field force in India/Brazil, high entry barriers in chronic segments, and a proven track record of integrating acquisitions. These are sustainable due to the long-term nature of chronic prescriptions.

Macro Economic Sensitivity

Sensitive to healthcare spending trends and regulatory changes in India and Brazil. Inflation impacts SG&A expenses, which were INR 4,438 Cr (39% of revenue) in FY25.

Consumer Behavior

Increasing demand for chronic disease management (cardiac, gastro) drives steady volume growth in the India business.

Geopolitical Risks

Operations in Russia (Zao Torrent Pharma) and other emerging markets expose the company to regional political instability and trade barriers.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA manufacturing standards (cGMP) and price controls (DPCO in India). Dahej and Indrad facilities are currently under VAI (Voluntary Action Indicated) status.

Environmental Compliance

The company has instituted an ESG framework with four pillars: responsible consumption, practices, communication, and supply chain. It carries significant cyber security insurance.

Taxation Policy Impact

Effective tax rate was approximately 28.5% in FY25 (INR 762 Cr tax on INR 2,673 Cr PBT). The company faces potential tax exposure from cross-border transactions and varying international laws.

Legal Contingencies

Ongoing product liability litigation in the US regarding Losartan and Valsartan. One pending complaint from the Curatio merger was also noted.

⚠️ Risk Analysis

Key Uncertainties

Integration risk of the JB Chemicals acquisition (INR 25,689 Cr value) is a medium-term uncertainty. USFDA regulatory status of manufacturing plants can impact 10-15% of revenue if escalations occur.

Geographic Concentration Risk

High concentration in India (55% of revenue). Any regulatory change in the Indian Pharmaceutical Market (IPM) significantly impacts the consolidated profile.